tetano
Editor, Senior Moderator
Cell Rep Med
. 2020 Sep 24;100123.
doi: 10.1016/j.xcrm.2020.100123. Online ahead of print.
ReScan, a Multiplex Diagnostic Pipeline, Pans Human Sera for SARS-CoV-2 Antigens
Colin R Zamecnik[SUP] 1 [/SUP], Jayant V Rajan[SUP] 2 [/SUP], Kevin A Yamauchi[SUP] 3 [/SUP], Sabrina A Mann[SUP] 3 4 [/SUP], Rita P Loudermilk[SUP] 1 [/SUP], Gavin M Sowa[SUP] 5 [/SUP], Kelsey C Zorn[SUP] 4 [/SUP], Bonny D Alvarenga[SUP] 1 [/SUP], Christian Gaebler[SUP] 6 [/SUP], Marina Caskey[SUP] 6 [/SUP], Mars Stone[SUP] 7 8 [/SUP], Philip J Norris[SUP] 7 8 9 [/SUP], Wei Gu[SUP] 8 [/SUP], Charles Y Chiu[SUP] 8 9 [/SUP], Dianna Ng[SUP] 9 [/SUP], James R Byrnes[SUP] 10 [/SUP], Xin X Zhou[SUP] 10 [/SUP], James A Wells[SUP] 10 11 [/SUP], Davide F Robbiani[SUP] 6 [/SUP], Michel C Nussenzweig[SUP] 6 12 [/SUP], Joseph L DeRisi[SUP] 3 4 [/SUP], Michael R Wilson[SUP] 1 [/SUP]
Affiliations
Abstract
Comprehensive understanding of the serological response to SARS-CoV-2 infection is important for both pathophysiologic insight and diagnostic development. Here, we generate a pan-human coronavirus programmable phage display assay to perform proteome-wide profiling of coronavirus antigens enriched by 98 COVID-19 patient sera. Next, we employ ReScan, a method to efficiently sequester phage expressing the most immunogenic peptides and print them onto paper-based microarrays using acoustic liquid handling, which isolates and identifies 9 candidate antigens, 8 of which are derived from the 2 proteins used for SARS-CoV-2 serologic assays: spike and nucleocapsid proteins. After deployment in a high-throughput assay amenable to clinical lab settings, these antigens show improved specificity over a whole protein panel. This proof-of-concept study demonstrates that ReScan will have broad applicability for other emerging infectious diseases or autoimmune diseases that lack a valid biomarker, enabling a seamless pipeline from antigen discovery to diagnostic using one recombinant protein source.
. 2020 Sep 24;100123.
doi: 10.1016/j.xcrm.2020.100123. Online ahead of print.
ReScan, a Multiplex Diagnostic Pipeline, Pans Human Sera for SARS-CoV-2 Antigens
Colin R Zamecnik[SUP] 1 [/SUP], Jayant V Rajan[SUP] 2 [/SUP], Kevin A Yamauchi[SUP] 3 [/SUP], Sabrina A Mann[SUP] 3 4 [/SUP], Rita P Loudermilk[SUP] 1 [/SUP], Gavin M Sowa[SUP] 5 [/SUP], Kelsey C Zorn[SUP] 4 [/SUP], Bonny D Alvarenga[SUP] 1 [/SUP], Christian Gaebler[SUP] 6 [/SUP], Marina Caskey[SUP] 6 [/SUP], Mars Stone[SUP] 7 8 [/SUP], Philip J Norris[SUP] 7 8 9 [/SUP], Wei Gu[SUP] 8 [/SUP], Charles Y Chiu[SUP] 8 9 [/SUP], Dianna Ng[SUP] 9 [/SUP], James R Byrnes[SUP] 10 [/SUP], Xin X Zhou[SUP] 10 [/SUP], James A Wells[SUP] 10 11 [/SUP], Davide F Robbiani[SUP] 6 [/SUP], Michel C Nussenzweig[SUP] 6 12 [/SUP], Joseph L DeRisi[SUP] 3 4 [/SUP], Michael R Wilson[SUP] 1 [/SUP]
Affiliations
- PMID: 32995758
- PMCID: PMC7513813
- DOI: 10.1016/j.xcrm.2020.100123
Abstract
Comprehensive understanding of the serological response to SARS-CoV-2 infection is important for both pathophysiologic insight and diagnostic development. Here, we generate a pan-human coronavirus programmable phage display assay to perform proteome-wide profiling of coronavirus antigens enriched by 98 COVID-19 patient sera. Next, we employ ReScan, a method to efficiently sequester phage expressing the most immunogenic peptides and print them onto paper-based microarrays using acoustic liquid handling, which isolates and identifies 9 candidate antigens, 8 of which are derived from the 2 proteins used for SARS-CoV-2 serologic assays: spike and nucleocapsid proteins. After deployment in a high-throughput assay amenable to clinical lab settings, these antigens show improved specificity over a whole protein panel. This proof-of-concept study demonstrates that ReScan will have broad applicability for other emerging infectious diseases or autoimmune diseases that lack a valid biomarker, enabling a seamless pipeline from antigen discovery to diagnostic using one recombinant protein source.